Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

Video

Uncovering the Path to Successful Biosimilar Adoption for Your Specialty Practice

If your specialty practice is preparing to adopt biosimilars, McKesson can help. We clear the path by creating a roadmap for success. Our advisors and resources can help you navigate every step of the biosimilar journey, from patient education to developing training programs. McKesson also supports specialty practices like yours with communicating the facts clearly, implementing efficient workflows and driving operational excellence so you can focus on what matters most - caring for your patients.

 

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

Contact Us
Specialty Distribution

Specialty drugs for physician practices.

Physician practice login.

Pharmacy Distribution

For pharmacies, health systems & hospitals.

New to biosimilars?

  • Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
  • While biosimilars are similar to their reference biological product, they are not generic equivalents.
  • Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

 

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through McKesson Include:

 

Biosimilar Drug

Biologic Reference Drug

HCPCS Code 

Patient Support Services

Full Prescribing Information

Alymsys
(bevacizumab-maly)

Avastin

Q5126

 (PDF, 588 KB)

Mvasi
(bevacizumab-awwb)

Avastin

Q5107

 (PDF, 627 KB)

Vegzelma
(bevacizumab-adcd)

Avastin

Q5129

 (PDF, 653 KB)

Zirabev
(bevacizumab-bvzr)

Avastin

Q5118

 (PDF, 1 MB)

Retacrit
(epoetin alfa-epbx)

Epogen/Procrit

Q5105 (ESRD use)
Q5106 (non-ESRD use)

 (PDF, 614 KB)

Herzuma
(trastuzumab-pkrb)

Herceptin

Q5113

 (PDF, 551 KB)

Kanjinti
(trastuzumab-anns)

Herceptin

Q5117

 (PDF, 834 KB)

Ogivri
(trastuzumab-dkst)

Herceptin

Q5114

Ontruzant
(trastuzumab-dttb)

Herceptin

Q5112

Trazimera
(trastuzumab-qyyp)

Herceptin

Q5116

 (PDF, 706 KB)

Amjevita
(adalimumab-atto)

Humira

 

Amjevita Support

Byooviz
(ranibizumab-nuna)

Lucentis

Q5124

 (PDF, 685 KB)

Cimerli
(ranibizumab-eqrn)

Lucentis

Q5128

 (PDF, 1.41 MB)

Fulphila
(pegfilgrastim-jmdb)

Neulasta

Q5108

 (PDF, 921 KB)

Fylnetra
(pegfilgrastim-pbbk)

Neulasta

Q5130

 (PDF, 1.25 MB)

Nyvepria
(pegfilgrastim-apgf)

Neulasta

Q5122

 (PDF, 1 MB)

Stimufend
(pegfilgrastim-fpgk)

Neulasta

Q5127

 (PDF, 546 KB)

Udenyca
(pegfilgrastim-cbqv)

Neulasta

Q5111

 (PDF, 1 MB)

Ziextenzo
(pegfilgrastim-bmez)

Neulasta

Q5120

Nivestym
(filgrastim-aafi)

Neupogen

Q5110

 (PDF, 921 KB)

Releuko
(filgrastim-ayow)

Neupogen

Q5125

 (PDF, 4 MB)

Zarxio
(filgrastim-sndz)

Neupogen

Q5101

Avsola
(infliximab-axxq)

Remicade

Q5121

  

Inflectra
(infliximab-dyyb)

Remicade

Q5103

 (PDF, 1 MB)

Renflexis
(infliximab-abda)

Remicade

Q5104

 (PDF, 537 KB)

Riabni
(rituximab-arrx)

Rituxan

Q5123

 (PDF, 468 KB)

Ruxience
(rituximab-pvvr)

Rituxan

Q5119

 (PDF, 811 KB)

Truxima
(rituximab-abbs)

Rituxan

Q5115

 (PDF, 402 KB)

 

Four Reasons to Consider Adopting Biosimilars for Your Treatment Regimens

Expand Treatment Options for Complex Diseases

Substantial Cost Savings on Expensive Therapies

FDA-Approved, Safe and Effective Treatments

Support from FDA and Other Leading Medical Advisory Organizations

ADDITIONAL READING

Biosimilar Perspectives from McKesson Experts


McKesson’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.


An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.


Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.


Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.


A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.

Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.

Viewpoint

Biosimilar Endorsements From Major Medical Advisory Organizations

Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.

|  (PDF, 648 KB)

Education


Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.


Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.